The team reported their results in JAMA Internal Medicine on December 13.

While the therapy, the team found, provided no improvement in the overall survival of COVID-19 patients says Santin, it shouldn’t be ruled out in early pandemic cases where no other treatment options are available. To investigate the success of convalescent plasma therapy in reducing the severity and mortality of COVID-19, a team of researchers from seven institutions came together, including Alessandro Santin, MD, professor of obstetrics, gynecology, and reproductive sciences, and Mahalia Desruisseaux, MD, associate professor of internal medicine (infectious disease), who led the portion of the clinical trial done at Yale School of Medicine. But since the therapy’s emergency use authorization by the Food and Drug Administration in August 2020, its supposed benefits have been met with scrutiny by some researchers.

Convalescent plasma therapy was one of the first treatments available in the battle against COVID-19.

State of survival plasma cores